Environmental News for a Healthier Planet and Life

Johnson & Johnson Pauses COVID-19 Vaccine Trial After Mystery Illness

Health + Wellness
Johnson & Johnson Pauses COVID-19 Vaccine Trial After Mystery Illness
Pharmaceutical giant Johnson & Johnson is pausing its COVID-19 vaccine trials after a study participant fell ill. Lubo Ivanko / Getty Images

Pharmaceutical giant Johnson & Johnson (J&J) announced that it is pausing COVID-19 vaccine trials after a study participant fell ill. The announcement comes just weeks after the company said trials were in the final stages, NBC News reported.

J&J told STAT that the pause was due to "an unexplained illness in a study participant," but would not provide more details citing the patient's privacy. The company added that it needs to gather more information before sharing any details. J&J does not yet know if the participant received the vaccine-candidate or the placebo.

"Following our guidelines, the participant's illness is being reviewed and evaluated by the ENSEMBLE independent Data Safety Monitoring Board as well as our internal clinical and safety physicians," the company said in a statement. "Adverse events — illnesses, accidents, etc. — even those that are serious, are an expected part of any clinical study, especially large studies."

Pauses are not uncommon, NBC News reported, but rather a testament to upholding regulatory standards. AstraZeneca paused its vaccine trial last month when a study participant in the UK also fell ill with an unexplained illness.

While the 60,000-patient trial is paused, it's different from a clinical hold, which is a longer regulatory procedure. In fact, it is rare for J&J to disclose study pauses to the public, STAT reported.

"A study pause, in which recruitment or dosing is paused by the study sponsor, is a standard component of a clinical trial protocol," J&J said in the statement. "A regulatory hold of a clinical trial is a requirement by a regulatory health authority, such as the U.S. Food and Drug Administration. As outlined in our transparency commitments, we proactively disclose any regulatory hold of a pivotal clinical trial."

J&J CFO Joseph Wolk told CNBC that the company was acting responsibly. "We're letting safety protocol follow proper procedure here," he said. "What it should also do is reassure the public that every scientific, medical and ethical standard is being applied here."

Experts also pointed out the importance of study pauses.

"This is completely expected, and it's just a reminder how ridiculous it is to try and meet a political timeline of having a vaccine before Nov. 3," Ashish Jha, dean of the Brown University School of Public Health, told CNN.

J&J is the fourth pharmaceutical company receiving funding under Operation Warp Speed to enter late-stage testing of its vaccine candidate. Moderna, AstraZeneca and Pfizer are all in the process of evaluating safety and efficacy data of their clinical trials, CNBC reported.

Eat Just's cell-based chicken nugget is now served at Singapore restaurant 1880. Eat Just, Inc.

At a time of impending global food scarcity, cell-based meats and seafood have been heralded as the future of food.

Read More Show Less

EcoWatch Daily Newsletter

New Zealand sea lions are an endangered species and one of the rarest species of sea lions in the world. Art Wolfe / Photodisc / Getty Images

One city in New Zealand knows what its priorities are.

Dunedin, the second largest city on New Zealand's South Island, has closed a popular road to protect a mother sea lion and her pup, The Guardian reported.

Read More Show Less


piyaset / iStock / Getty Images Plus

In an alarming new study, scientists found that climate change is already harming children's diets.

Read More Show Less
Wildfires within the Arctic Circle in Alaska on June 4, 2020. Contains modified Copernicus Sentinel data processed by Pierre Markuse. CC BY 2.0

By Jeff Masters, Ph.D.

Earth had its second-warmest year on record in 2020, just 0.02 degrees Celsius (0.04°F) behind the record set in 2016, and 0.98 degrees Celsius (1.76°F) above the 20th-century average, NOAA reported January 14.

Read More Show Less

In December of 1924, the heads of all the major lightbulb manufacturers across the world met in Geneva to concoct a sinister plan. Their talks outlined limits on how long all of their lightbulbs would last. The idea is that if their bulbs failed quickly customers would have to buy more of their product. In this video, we're going to unpack this idea of purposefully creating inferior products to drive sales, a symptom of late-stage capitalism that has since been coined planned obsolescence. And as we'll see, this obsolescence can have drastic consequences on our wallets, waste streams, and even our climate.

Read More Show Less